CLOs on the Move

Medically Home

www.medicallyhome.com

 
We bring the hospital to you! We deliver advanced medical care to where and when patients and their families want and need it. The Medically Home Program gives you more care over a longer period of time. We know getting well from a hospital-level illness or surgical procedure takes weeks, not days. With the Medically Home Program, you get the time you need - at home - with a single care team available to you the entire time. One of the secrets to getting better is being involved in – and understanding – your own care. The more time you ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Kyle Seiter
 Chief Information Officer Profile
William Kramer
 Chief Legal Counsel Profile

Similar Companies

Uams/Ecco Head Start Program

Uams/Ecco Head Start Program is a Little Rock, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ambulatory Care Affiliates

Ambulatory Care Affiliates, Ltd. is a New Albany, OH-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Landmark Health Solutions Company

Landmark Health Solutions Company is a Haverhill, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kimberly-Clark

Kimberly-Clark Corporation is an American multinational personal care corporation that produces mostly paper-based consumer products.

PanOptica

At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.